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Haemoglobin therapeutics in clinical practice
Jean-François Baron
Early approaches to the development of oxygen carriers involved the use of
stroma-free hemoglobin solutions. These solutions did not require blood typing
or crossmatching and could be stored for long periods. In addition, a variety of
methods have been developed in chemically modifying and stabilizing the
hemoglobin molecule. Several hemoglobin therapeutics are now in clinical trials
as temporary alternatives to blood or as therapeutic agents for ischemia. The
various hemoglobin products under development are derived from three principal
sources: human, bovine and genetically engineered hemoglobin. Diaspirin cross-
linked hemoglobin (DCLHb), administered at doses ranging from approximately
20–1000ml, has been investigated in a number of clinical trials in patients
undergoing orthopedic, abdominal aortic repair, major abdominal surgery,
cardiac surgery and in critically ill patients with septic shock. In several studies,
DCLHb was effective in avoiding the transfusion. However, Baxter Healthcare
Corporation (Chicago, Illinois, USA) stopped the development of DCLHb after
two unsuccessful trials in trauma patients. Bovine polymerized hemoglobin has
also been extensively studied. Several phase II and phase III trials have been
performed with this product in hemorrhagic surgery, cardiac surgery and
vascular surgery, but data have not yet been published. Hemoglobin therapeutics
could provide an important new option as an alternative to blood transfusion.
Furthermore, they may be able to provide an immediate on-site replacement for
traumatic blood loss, prevent global ischemia and organ failure, treat focal
ischemia, and provide effective hemodynamic support for septic shock-induced
hypotension.
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Introduction
A number of oxygen-carrying alternatives to blood have
been in clinical evaluation since Amberson [1] adminis-
tered haemoglobin–saline solutions in clinical trials. Four-
teen patients received an injection of a haemoglobin–
saline solution. Of these, five patients with secondary
anaemia due to haemorrhage or infection received multi-
ple injections, and three of these patients showed clinical
improvement, consisting of increased haemoglobin and
haematocrit values and reticulocytosis. The use of these
early haemoglobin solutions had a number of drawbacks,
however, including signs of renal impairment, resulting
from short intravascular persistence and impurities of the
haemoglobin introduced during preparation. The first
generation of haemoglobin therapeutics has addressed the
infectious disease risk, storage, stability and typing issues.
These solutions have the potential to augment the
oxygen-carrying capacity of patients’ red blood cells tem-
porarily and help avoid allogenic transfusion.
Sources of haemoglobin
Early approaches to the development of oxygen carriers
involved the use of stroma-free haemoglobin solutions [2].
These solutions did not require blood typing or cross-
matching and could be stored for long periods. It was dis-
covered, however, that removal of haemoglobin from red
cells leads to the loss of 2,3-diphosphoglycerate and
diminished oxygen-delivery characteristics. Furthermore,
haemoglobin tetramers tend to dissociate into dimers,
which have a short intravascular persistence (due to rapid
renal excretion) and a nephrotoxic action secondary to
dimer precipitation in the proximal tubule [3]. Therefore,
in recent years, a variety of methods have been developed
to prevent these problems by chemically modifying and
stabilizing the haemoglobin molecule. Several haemoglo-
bin therapeutics are now in clinical trials as temporary
alternatives to blood or as therapeutic agents for
ischaemia. The various haemoglobin products under
development are derived from three principal sources:
human, bovine and genetically engineered haemoglobin.
The rationale for using human haemoglobin is related to
the reduced risk of causing allergic or other immune reac-
tions in the recipient. The viral risks associated with blood
transfusions, already reduced by extensive donation
screening tests, are greatly minimized during the haemo-
globin therapeutic manufacturing process by rigorous
viral-inactivation procedures. Some chemically stabilized
DCLHb = diaspirin cross-linked haemoglobin; HBOC = haemoglobin-based oxygen carrier.haemoglobin solutions, such as diaspirin cross-linked
haemoglobin (DCLHb or HemAssist™, Baxter Health-
care Corporation, Chicago, Illinois, USA) are subjected to
ultrafiltration and heat treatment during the manufactur-
ing process to inactivate viruses [4]. Other human haemo-
globin-based products are currently being developed,
including pyridoxylated and glutaraldehyde polymerised
haemoglobin (PolyHeme™, Northfield Laboratories Inc,
Evanston, Illinois, USA), o-raffinose cross-linked and
polymerised haemoglobin (HemoLink™, Hemosol Inc,
Toronto, Canada) and pyridoxylate haemoglobin poly-
oxyethylene (Apex Corporation, Plainfield, Illinois, USA).
Bovine haemoglobin is readily available and, potentially,
has a lower cost as a raw material than human haemoglobin
[5,6]. Like human haemoglobin, however, bovine haemo-
globin requires modification to be clinically effective. Fur-
thermore, infectious agents present in animal blood, such
as the bovine spongiform encephalopathy prion, are not as
well characterized and therefore are more difficult to
detect than those in human blood. Animal-sourced prod-
ucts must also be subjected to rigorous purification proce-
dures, because contamination with animal-derived proteins
may cause allergic reactions in humans. Bovine haemoglo-
bin is usually derived from protected herds in countries
without bovine spongiform encephalopathy incidence,
however. In addition, the specific purification techniques
used may be able to eliminate the protein responsible for
bovine spongiform encephalopathy transmission, even
though the nature of the protein is unknown. A bovine
haemoglobin product was recently approved for veterinary
use in canines (Oxyglobin™, Biopure Corp, Cambridge,
Massachusetts, USA). A second bovine haemoglobin, glu-
taraldehyde polymerized bovine haemoglobin (Hemop-
ure™, Biopure Corp), is in a phase III human clinical trial
in Europe. This product was also tested in patients in
sickle cell crisis without producing side effects [7]. A third
bovine-derived product, polyethylene-glycol conjugated
bovine haemoglobin (Enzon Inc, Piscataway, New Jersey,
USA) is also under investigation.
Recombinant technology is also being investigated to
engineer oxygen-carrying solutions. These techniques
allow flexibility in product design, enabling haemoglobin
molecules to be modified to address specific clinical
needs. In addition, many of the potential side effects of
bovine-sourced products, or indeed the sourcing complica-
tions associated with human red blood cells, may be
avoided by using recombinant technology. Purification
requirements for recombinant products are quite high, but
the source material is theoretically unlimited. The only
recombinant haemoglobin subjected to clinical trials is
obtained by genetic engineering from Escherichia coli and
is a modified human haemoglobin tetramer cross-linked
with a glycine bridge between the a-subunits (Optro™,
Somatogen Inc, Boulder, Colorado, USA) [8]. Pilot studies
of tolerance were carried out on 24 volunteers [9]. No
renal, hepatic, or pulmonary toxicity was noted. There was
no renal excretion, and no significant variation in either
systolic or diastolic arterial blood pressure. Fever, higher
than 38°C, occurred 3–8h after infusion in 12 individuals,
with headache, myalgia and chills. No further episodes of
fever were noted after improving the purification process.
Further clinical development of this product has been
stopped, however, pending new generations of recombi-
nant haemoglobin solutions. The possibility of obtaining
haemoglobin from transgenic tobacco plants was recently
reported [10].
Cross-linked haemoglobins
The most extensively studied of the modified haemoglo-
bins, is diaspirin cross-linked haemoglobin (DCLHb) or
HemAssist™ (Baxter Corp.). DCLHb is produced using
3,5-dibromosalicylate to form a four-carbon fumarate
bridge between the two a-subunits of the haemoglobin
molecule. The stabilization of DCLHb during manufac-
ture not only permits heat treatment, but also induces the
haemoglobin to assume a low-affinity conformation similar
to that in the human red blood cell in the presence of 2,3-
diphosphoglycerate. Consequently, DCLHb has similar
oxygen-carrying properties to those of fresh blood.
However, DCLHb has a slightly lower affinity for oxygen
than fresh blood (right shifted oxygen dissociation curve),
which allows it to release oxygen more readily to tissues
compared with red blood cells.
DCLHb has been extensively studied in preclinical
studies with excellent results [11–15]. In animal models of
haemorrhagic shock, DCLHb was more effective than
infusion of large volumes of lactated Ringer’s solution in
restoring arterial blood pressure and tissue oxygenation
[16]. In preclinical studies, the safety profile was also
excellent without undesirable effects such as antigenicity,
complement or white blood cell activation or renal toxic-
ity. An early and sustained increase in mean arterial pres-
sure associated with a decreased heart rate was frequently
reported [11,17–19]. This pressure increase is dose depen-
dent and is easily controlled using antihypertensive
agents. Three mechanisms may contribute to the vaso-
pressive effect of DCLHb: nitric oxide scavenging [20],
stimulation of endothelin release [20], and sensitization of
a-adrenergic receptors [21].
DCLHb, administered at doses ranging from approxi-
mately 20 to 1000ml, has been investigated in a number
of clinical trials in patients undergoing orthopaedic
surgery, abdominal aortic repair and major abdominal
surgery [22], and in critically ill patients with septic shock
[23]. In these completed studies, involving more than 700
patients, safety assessments indicated that DCLHb was
well tolerated. In a small study [22], DCLHb (750ml)
effectively eliminated the need for any transfusions of
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patients undergoing elective hip arthroplasty with high
blood loss. A larger trial in post bypass cardiac surgery
patients requiring transfusion was undertaken to deter-
mine the efficacy of DCLHb in reducing or preventing
the postoperative use of blood transfusions [24]. In that
multicenter study, 209 patients were enrolled when it was
determined that they required transfusion after bypass.
The patients randomly received up to three doses (total
750ml) of DCLHb or up to three units of packed red
blood cells within 24h after removal from bypass.
DCLHb was effective in avoiding the transfusion of
packed red blood cells in 59% of recipients on the day of
surgery, when all patients in the control group received
allogeneic blood. On the day after surgery, 39% of
patients receiving DCLHb had still avoided receiving
blood. At 7days after surgery, 19% of the DCLHb-treated
patients had completely avoided a transfusion of packed
red blood cells. The most common adverse reactions were
transient and nonserious, and consisted of hypertension,
yellowing of the skin (reported as jaundice), haemoglo-
binuria and hyperamylasaernia. There were no clinical
sequelae from these events. Two nonreported multicen-
ter studies have been conducted in trauma patients.
These trials have been stopped because of excessive mor-
tality in the treated group. Baxter subsequently stopped
the development of DCLHb.
Bovine haemoglobin
Bovine polymerized haemoglobin has also been exten-
sively studied. Standl et al [25] compared the effects of
stored red cells, freshly donated blood and ultrapurified
polymerized bovine haemoglobin [haemoglobin-based
oxygen carrier (HBOC)] on haemodynamic variables,
oxygen-transport capacity and muscular tissue oxygena-
tion after acute and almost complete isovolaemic haemod-
ilution in a canine model. The results showed a higher
oxygenation potential of HBOC than with autologous
stored red cells because of more pronounced oxygen
extraction. Horn et al [26] investigated the effect of HBOC
on skeletal muscle tissue oxygenation in comparison with
hetastarch during nearly complete arterial stenosis. After
isovolaemic haemodilution with Ringer’s lactate solution
to a haematocrit of 25%, a 95% artificial stenosis of the
popliteal artery was established. In both groups oxygen
delivery and oxygen consumption of the muscle decreased
in parallel to the decreasing blood flow during arterial
stenosis. In contrast, oxygen extraction ratio increased
after infusion of HBOC and was higher after the second
application when compared with hetastarch-treated
animals. During stenosis tissue oxygenation was decreased
and remained low after administration of hetastarch, but
increased to nearly baseline values after HBOC treatment,
suggesting that increased oxygen extraction in the HBOC
group is associated with improved skeletal muscle tissue
oxygenation during severe arterial stenosis.
In a whole-animal sheep model, Vlahakes et al [5] showed
in awake sheep that extreme haemodilution to a haemat-
ocrit of 2.4±0.5% was only tolerated when a polymerized
bovine haemoglobin solution was used, but not in animals
treated with hydroxyethyl starch devoid of oxygen-carry-
ing capacity. All of the animals that survived acute
haemodilution also survived the following 25days, without
evidence of renal or hepatic dysfunction. Similar results
were achieved recently when the blood of anesthetized
dogs was haemodiluted to a haematocrit of 2.0±1.8%
using a polymerized bovine haemoglobin solution [27].
Even at this extremely low haematocrit, the dogs were
haemodynamically stable, there was no evidence of lactic
acidosis and there were no histologic signs of ultrastruc-
tural destruction in liver and kidney.
Several phase II and III trials have been performed with
this product in haemorrhagic surgery, cardiac surgery and
vascular surgery, but data have not yet been published.
Future developments
The properties of haemoglobin therapeutics include effec-
tive transport and delivery of oxygen, much like red cells.
Unlike the red cell, however, the haemoglobin molecule in
solution appears to have positive effects on the microcircu-
lation of key tissues and organs, with easier penetration
into capillaries because of low molecular size and low solu-
tion viscosity. These properties and the vasopressor effects
suggest a number of potential therapeutic applications.
Considering the emergency use setting, haemoglobin
therapeutics may allow emergency department personnel
to avoid time-consuming and expensive cross-matching.
Haemoglobin therapeutics may allow more effective on-
scene or emergency department resuscitation of trauma
patients and reduced risk of organ failure secondary to the
hypoxic insult.
Furthermore, haemoglobin therapeutics can be formu-
lated to exert a colloid osmotic pressure which, combined
with the vasopressor activity, allows a rise in blood pres-
sure without any detrimental effects on regional perfusion.
As a result, haemoglobin therapeutics may be capable of
treating the hypotension, while maintaining regional per-
fusion, in patients with septic shock.
Other potential indications for haemoglobin therapeutics
include stroke and myocardial infarction, perfusion of
tumours to enhance cancer therapy, and sickle cell anaemia.
Haemoglobin therapeutics under investigation are rela-
tively short-lived compared with transfused red cells,
placing potential limits on their future applications.
Beyond these approaches, a range of other solutions that
may have longer intravascular persistence and could, there-
fore, be closer to the concept of blood substitutes are being
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haemoglobin, synthetic heme-embedded lipid micros-
pheres, and other oxygen-carrying artificial red cells.
Conclusion
Preclinical studies have shown haemoglobin therapeutics
to be as effective as blood and more effective than stan-
dard colloid or crystalloid solutions for resuscitation from
haemorrhagic and septic shock. In the early phases of clin-
ical trials, these solutions have been well tolerated, with
only minor side effects. Haemoglobin therapeutics could
provide an important new option for the treatment and
prevention of ischaemia resulting from hypoperfusion.
Furthermore, they may be able to provide an immediate
on-site replacement for traumatic blood loss, prevent
global ischaemia and organ failure, treat focal ischaemia,
and provide effective haemodynamic support for septic
shock-induced hypotension.
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